Supply of QUITX STEP 1 NICOTINE PATCHES 21mg/24 hours nicotine 52.5mg transdermal drug delivery system by Alphapharm Pty Limited

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that they meet safety, quality, and efficacy standards. The 1989 Act established a comprehensive regulatory framework to manage the importation, manufacture, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. This legislation was introduced to address the need for a unified regulatory system to protect public health by ensuring that therapeutic goods available in Australia are safe, of high quality, and effective for their intended use. Enacted by the Australian Parliament, the policy objective of the Therapeutic Goods Act 1989 is to safeguard the health and safety of the Australian population by regulating the therapeutic goods market effectively. This includes ensuring that therapeutic goods are appropriately labelled, among other requirements. This particular notice, issued by Mayada Kayali, a Delegate of the Secretary to the Department of Health and Ageing, gives consent under sections 14 and 14A of the Therapeutic Goods Act 1989 for Alphapharm Pty Limited to supply a specific batch of nicotine patches that do not fully comply with the labelling requirements of Therapeutic Goods Order No. 69. This consent is conditional on the patches meeting all other regulatory standards and applies only to the specified batch due to the non-compliance with certain labelling details.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, with specific sections such as 14 and 14A allowing for exceptions and consents under certain conditions. In this instance, the Delegate of the Secretary to the Department of Health and Ageing has issued a consent under sections 14 and 14A for Alphapharm Pty Limited to supply a particular batch of QUITX STEP 1 NICOTINE PATCHES 21mg/24 hours. This consent is narrowly tailored to address non-compliance with specific labelling requirements as outlined in Therapeutic Goods Order No. 69. The consent is strictly limited to the specified batch number 489800, which expires in October 2015, and is contingent on the goods meeting all other regulatory standards. This legislative action ensures that the therapeutic goods supplied meet the necessary health and safety standards while accommodating specific circumstances where full compliance with certain labelling details cannot be achieved.

Key Provisions

The Therapeutic Goods Act 1989 (section 14) authorises the Delegate to consent to certain variations in the labelling of therapeutic goods under specific circumstances. In this instance, section 14A grants the Delegate, Mayada Kayali, the authority to permit Alphapharm Pty Limited to supply QUITX STEP 1 NICOTINE PATCHES 21mg/24 hours nicotine 52.5mg transdermal drug delivery system (AUST R 77927), which does not fully comply with the labelling standards stipulated under subclause 3(12)(b) of the Therapeutic Goods Order No. 69. This non-compliance relates to the batch and expiry details on the sachet labels not being prefixed with the required prefixes. However, section 15(1) of the Act stipulates that such consent is conditional, ensuring that the goods meet all other aspects of the standard. The obligations imposed by the Act on the parties involved are clear. Alphapharm Pty Limited must ensure that the nicotine patches supplied comply with all regulatory standards except for the specific labelling issue addressed by the consent. The company must also adhere to the condition that this consent applies solely to batch number 489800, which is set to expire in October 2015. This ensures that the non-compliance is limited to a specific product batch and timeframe, thereby maintaining the overall integrity of the therapeutic goods supply. In terms of consequences for non-compliance, the Therapeutic Goods Act 1989 outlines various offences and penalties. For example, section 34 of the Act states that any person who contravenes the Act or any regulations or standards under the Act may be subject to civil or criminal penalties. The maximum penalties can include substantial fines and, in severe cases, imprisonment. Specifically, section 33A outlines that a corporation can be fined up to $2,100,000 for serious or repeated breaches, while individuals can face fines up to $210,000 and imprisonment for up to five years for the most egregious violations. These stringent measures underscore the importance of adhering to the Act's requirements and the potential severe repercussions for non-compliance.